Modelling and treating amyotrophic lateral sclerosis through induced-pluripotent stem cells technology - PubMed (original) (raw)
Review
Modelling and treating amyotrophic lateral sclerosis through induced-pluripotent stem cells technology
Delphine Bohl et al. Curr Stem Cell Res Ther. 2016.
Abstract
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease affecting primarily the population of motor neurons, even though a non-cell autonomous component, involving neighbouring non-neuronal cells, is more and more described. Despite 140 years of disease experience, still no efficient treatment exists against ALS. The inability to readily obtain the faulty cell types relevant to ALS has impeded progress in drug discovery for decades. However, the pioneer work of Shinya Yamanaka in 2007 in the stem cell field was a real breakthrough. Recent advances in cell reprogramming now grant access to significant quantities of CNS disease-affected cells. Induced pluripotent stem cells (iPSc) have been recently derived from patients carrying mutations linked to familial forms of ALS as well as from sporadic patients. Precise and mature protocols allow now their differentiation into ALS-relevant cell subtypes; sustainable and renewable sources of human motor neurons or glia are being available for ALS disease modelling, drug screening or for the development of cell therapies. In few years, the proof-of-concept was made that ALS disease-related phenotypes can be reproduced with iPSc and despite some remaining challenges, we are now not so far to provide platforms for the investigation of ALS therapeutics. This paper also reviews the pioneering studies regarding the applicability of iPSc technology in ALS animal models. From modest slowing down of ALS progression to no severe adverse effects, iPSc-based cell therapy resulted in promising premises in ALS preclinical paradigms, although long-term surveys are highly recommended.
Similar articles
- Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y, Deng W. Liu Y, et al. Brain Res. 2016 May 1;1638(Pt A):30-41. doi: 10.1016/j.brainres.2015.09.023. Epub 2015 Sep 28. Brain Res. 2016. PMID: 26423934 Free PMC article. Review. - A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells.
Burkhardt MF, Martinez FJ, Wright S, Ramos C, Volfson D, Mason M, Garnes J, Dang V, Lievers J, Shoukat-Mumtaz U, Martinez R, Gai H, Blake R, Vaisberg E, Grskovic M, Johnson C, Irion S, Bright J, Cooper B, Nguyen L, Griswold-Prenner I, Javaherian A. Burkhardt MF, et al. Mol Cell Neurosci. 2013 Sep;56:355-64. doi: 10.1016/j.mcn.2013.07.007. Epub 2013 Jul 25. Mol Cell Neurosci. 2013. PMID: 23891805 Free PMC article. - Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets.
Ferraiuolo L, Maragakis NJ. Ferraiuolo L, et al. Neurosci Lett. 2021 Jun 11;755:135911. doi: 10.1016/j.neulet.2021.135911. Epub 2021 Apr 20. Neurosci Lett. 2021. PMID: 33892003 Review. - Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis.
Lee JH, Liu JW, Lin SZ, Harn HJ, Chiou TW. Lee JH, et al. Cell Transplant. 2018 Sep;27(9):1301-1312. doi: 10.1177/0963689718785154. Epub 2018 Jul 23. Cell Transplant. 2018. PMID: 30033758 Free PMC article. Review. - Stem cells for amyotrophic lateral sclerosis modeling and therapy: myth or fact?
Coatti GC, Beccari MS, Olávio TR, Mitne-Neto M, Okamoto OK, Zatz M. Coatti GC, et al. Cytometry A. 2015 Mar;87(3):197-211. doi: 10.1002/cyto.a.22630. Epub 2015 Feb 2. Cytometry A. 2015. PMID: 25645594 Review.
Cited by
- From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis.
Morello G, Salomone S, D'Agata V, Conforti FL, Cavallaro S. Morello G, et al. Front Neurosci. 2020 Oct 30;14:577755. doi: 10.3389/fnins.2020.577755. eCollection 2020. Front Neurosci. 2020. PMID: 33192262 Free PMC article. Review. - Altered Features of Vimentin-containing Cells in Cerebrum of Tg(SOD1*G93A)1Gur Mice: A Preliminary Study on Cerebrum Endogenous Neural Precursor Cells in Amyotrophic Lateral Sclerosis.
Tang C, Zhu L, Zhou Q, Li M, Zhu Y, Xu Z, Lu Y, Xu R. Tang C, et al. Int J Biol Sci. 2019 Nov 1;15(13):2830-2843. doi: 10.7150/ijbs.33461. eCollection 2019. Int J Biol Sci. 2019. PMID: 31853221 Free PMC article. - Human Oral Mucosa Stem Cells Increase Survival of Neurons Affected by In Vitro Anoxia and Improve Recovery of Mice Affected by Stroke Through Time-limited Secretion of miR-514A-3p.
Stančin P, Song MS, Alajbeg I, Mitrečić D. Stančin P, et al. Cell Mol Neurobiol. 2023 Jul;43(5):1975-1988. doi: 10.1007/s10571-022-01276-7. Epub 2022 Sep 9. Cell Mol Neurobiol. 2023. PMID: 36083390 Free PMC article. - Using induced pluripotent stem cells derived neurons to model brain diseases.
McKinney CE. McKinney CE. Neural Regen Res. 2017 Jul;12(7):1062-1067. doi: 10.4103/1673-5374.211180. Neural Regen Res. 2017. PMID: 28852383 Free PMC article. Review. - Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.
Liu E, Karpf L, Bohl D. Liu E, et al. Front Mol Neurosci. 2021 Dec 14;14:767041. doi: 10.3389/fnmol.2021.767041. eCollection 2021. Front Mol Neurosci. 2021. PMID: 34970118 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous